Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

BACKGROUND: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannetta, Marco, Cesta, Novella, Stingone, Christof, Malagnino, Vincenzo, Teti, Elisabetta, Vitale, Pietro, De Simone, Giuseppe, Rossi, Benedetta, Ansaldo, Lorenzo, Compagno, Mirko, Spalliera, Ilaria, Di Lorenzo, Andrea, Landi, Doriana, Nicoletti, Carolina Gabri, Marfia, Girolama Alessandra, Andreoni, Massimo, Sarmati, Loredana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399651/
https://www.ncbi.nlm.nih.gov/pubmed/32777745
http://dx.doi.org/10.1016/j.msard.2020.102442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399651/
https://www.ncbi.nlm.nih.gov/pubmed/32777745
http://dx.doi.org/10.1016/j.msard.2020.102442

Ejemplares similares